2.14 USD
-1.42 (-39.89%)
2.28 USD
+0.14 (+6.54%)
EGRX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. There are concerns on the financial health of EGRX while its profitability can be described as average. EGRX is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
EGRX had positive earnings in the past year.
In the past year EGRX has reported a negative cash flow from operations.
Of the past 5 years EGRX 4 years were profitable.
In the past 5 years EGRX always reported a positive cash flow from operatings.
1.2 Ratios
EGRX has a Return On Assets of 2.99%. This is amongst the best in the industry. EGRX outperforms 94.01% of its industry peers.
EGRX's Return On Equity of 4.80% is amongst the best of the industry. EGRX outperforms 94.54% of its industry peers.
EGRX has a better Return On Invested Capital (10.53%) than 95.77% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EGRX is below the industry average of 18.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| ROIC | 10.53% |
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
1.3 Margins
With an excellent Profit Margin value of 4.70%, EGRX belongs to the best of the industry, outperforming 94.19% of the companies in the same industry.
In the last couple of years the Profit Margin of EGRX has declined.
With an excellent Operating Margin value of 16.47%, EGRX belongs to the best of the industry, outperforming 95.77% of the companies in the same industry.
In the last couple of years the Operating Margin of EGRX has declined.
EGRX has a better Gross Margin (69.86%) than 84.33% of its industry peers.
EGRX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.47% | ||
| PM (TTM) | 4.7% | ||
| GM | 69.86% |
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EGRX is creating some value.
EGRX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, EGRX has a worse debt to assets ratio.
2.2 Solvency
EGRX has an Altman-Z score of 1.81. This is not the best score and indicates that EGRX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of EGRX (1.81) is better than 70.07% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that EGRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.25, EGRX is doing worse than 68.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.81 |
ROIC/WACC1.32
WACC7.97%
2.3 Liquidity
A Current Ratio of 2.16 indicates that EGRX has no problem at all paying its short term obligations.
EGRX has a worse Current ratio (2.16) than 75.35% of its industry peers.
EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
EGRX has a worse Quick ratio (1.67) than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.16 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
EGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.52%.
Measured over the past years, EGRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.81% on average per year.
The Revenue has decreased by -5.40% in the past year.
The Revenue has been growing slightly by 5.99% on average over the past years.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
3.2 Future
EGRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.47% yearly.
The Revenue is expected to grow by 0.24% on average over the next years.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 0.46 indicates a rather cheap valuation of EGRX.
Based on the Price/Earnings ratio, EGRX is valued cheaply inside the industry as 99.82% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of EGRX to the average of the S&P500 Index (26.56), we can say EGRX is valued rather cheaply.
With a Price/Forward Earnings ratio of 0.64, the valuation of EGRX can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EGRX indicates a rather cheap valuation: EGRX is cheaper than 99.65% of the companies listed in the same industry.
EGRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.79, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.46 | ||
| Fwd PE | 0.64 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EGRX is valued cheaply inside the industry as 99.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.31 |
4.3 Compensation for Growth
EGRX has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as EGRX's earnings are expected to decrease with -26.94% in the coming years.
PEG (NY)N/A
PEG (5Y)0.03
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
5. Dividend
5.1 Amount
No dividends for EGRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.14
-1.42 (-39.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.05%
Inst Owner Change-82.05%
Ins Owners5.97%
Ins Owner Change0%
Market Cap27.80M
Revenue(TTM)257.50M
Net Income(TTM)12.10M
Analysts85.71
Price Target17.34 (710.28%)
Short Float %0.37%
Short Ratio0.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)10.18%
Max EPS beat(2)17.65%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)10.18%
Max EPS beat(4)29.93%
EPS beat(8)5
Avg EPS beat(8)-2.39%
EPS beat(12)8
Avg EPS beat(12)72.12%
EPS beat(16)11
Avg EPS beat(16)63.08%
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)2.71%
Max Revenue beat(2)6.76%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-7.39%
Max Revenue beat(4)6.76%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)5
Avg Revenue beat(12)-7.18%
Revenue beat(16)5
Avg Revenue beat(16)-7.22%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.46 | ||
| Fwd PE | 0.64 | ||
| P/S | 0.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.11 | ||
| P/tB | 0.28 | ||
| EV/EBITDA | 1.31 |
EPS(TTM)4.66
EY217.76%
EPS(NY)3.34
Fwd EY155.86%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS19.82
BVpS19.4
TBVpS7.67
PEG (NY)N/A
PEG (5Y)0.03
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| ROCE | 13.33% | ||
| ROIC | 10.53% | ||
| ROICexc | 11.06% | ||
| ROICexgc | 22.27% | ||
| OM | 16.47% | ||
| PM (TTM) | 4.7% | ||
| GM | 69.86% | ||
| FCFM | N/A |
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
ROICexc(3y)19.91%
ROICexc(5y)21.41%
ROICexgc(3y)52.27%
ROICexgc(5y)50.12%
ROCE(3y)17.2%
ROCE(5y)17.09%
ROICexgc growth 3Y46.01%
ROICexgc growth 5Y-6.15%
ROICexc growth 3Y27.58%
ROICexc growth 5Y-11.05%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
F-Score3
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 0.34% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 10.44 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.16 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.81 |
F-Score3
WACC7.97%
ROIC/WACC1.32
Cap/Depr(3y)10.4%
Cap/Depr(5y)10.3%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
EBIT growth 1Y-45.5%
EBIT growth 3Y67.47%
EBIT growth 5Y4.32%
EBIT Next Year-37.58%
EBIT Next 3Y-26.19%
EBIT Next 5YN/A
FCF growth 1Y-121.43%
FCF growth 3Y-2.92%
FCF growth 5Y-1.22%
OCF growth 1Y-120.96%
OCF growth 3Y-3.25%
OCF growth 5Y-2.96%
EAGLE PHARMACEUTICALS INC / EGRX FAQ
What is the fundamental rating for EGRX stock?
ChartMill assigns a fundamental rating of 4 / 10 to EGRX.
What is the valuation status for EGRX stock?
ChartMill assigns a valuation rating of 6 / 10 to EAGLE PHARMACEUTICALS INC (EGRX). This can be considered as Fairly Valued.
What is the profitability of EGRX stock?
EAGLE PHARMACEUTICALS INC (EGRX) has a profitability rating of 7 / 10.
What is the valuation of EAGLE PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for EAGLE PHARMACEUTICALS INC (EGRX) is 0.46 and the Price/Book (PB) ratio is 0.11.
What is the earnings growth outlook for EAGLE PHARMACEUTICALS INC?
The Earnings per Share (EPS) of EAGLE PHARMACEUTICALS INC (EGRX) is expected to decline by -40.26% in the next year.